DayTwo offers the scientific approach of diet therapy to combat diabetes
DAYTWO SECURES $31 MILLION IN SERIES B FINANCING TO SCALE MICROBIOME RESEARCH PLATFORM TO ADDRESS CHRONIC HEALTH CONDITIONS
DayTwo, the Only Microbiome Company with an Actionable Product Currently in the Market, Will Use Funding to Continue to Support the Fight Against Chronic Illnesses.
Tel Aviv, Israel & San Francisco, California – June 26, 2019 – DayTwo, the
microbiome human discovery platform that offers a glycemic control solution for
people with type 2 diabetes, announced $31 Million in Series B financing.
DayTwo will use the funding to accelerate go-to-market initiatives in the United States where the
company partners with payers, providers, and employers, and to continue to
develop a new generation of products and services for metabolic and
gastrointestinal conditions. The round was co-led by aMoon, the leading life sciences
venture fund, together with Ofek Ventures, a new venture fund
focused on disruptive ICT technologies. Existing investors Seventure Partners
and Johnson & Johnson continued their participation in the round. Previous
funding rounds included contributions from the Mayo Clinic for the company’s
validation trial, recently published in JAMA. The financing brings DayTwo’s total funding
to $48 Million.
“DayTwo is the only evidence-based,
actionable, microbiome platform in the market today. We are in a privileged
position to leverage our experience including first-rate science, clinical
trials in Israel and the United States, tens of thousands of customers, and
provider, employer, and payer relationships,” said Lihi Segal, CEO and
Founder of DayTwo. “This deep and broad foundation, coupled with this
financing, enables DayTwo to address the large and pressing clinical need to
bring food-as-medicine to market for people with type
2 diabetes in the United States.”
In addition, DayTwo is looking into corporation
with potential new partners to enter the Asia-Pacific markets, where more than 60% of the people with
diabetes live. India is an
important market in the world, thus DayTwo is open for opportunities from
potential partners in India.
DayTwo’s glycemic control solution uses gut
profiling and other clinical parameters to provide a food-as-medicine solution
to enable glycemic control. DayTwo’s personalized approach provides actionable
insights into how the body metabolizes food and allows individuals to navigate
what specific foods and meals to choose to balance their blood sugar levels.
DayTwo's glycemic control solution is more effective than existing protocols
for prediabetes and more impactful than leading diabetes pharmaceuticals.
"We are undergoing a transformational change in
healthcare, when technology and machine learning can benefit patients with
diabetes," said Yahal Zilka, Managing Partner at Ofek Ventures.
"After success in its initial market, we are excited to bring DayTwo to
the U.S. where it has the potential to improve the lives of over one hundred million
people with diabetes and prediabetes," added Mr. Zilka, whose investment track record includes Waze, Argus, Onavo, DesignArt, Magisto (acquired by Google),
Continental, Facebook, Qualcomm, and Vimeo, respectively.
“Digital health solutions such as DayTwo’s
accelerate treatment, disease prevention, and management of chronic illnesses,”
remarked Yair Schindel,
M.D., M.B.A., and Managing Partner aMoon Fund. “As a doctor who has witnessed first-hand
the harmful effects of metabolic diseases, I am encouraged by the positive
results among the tens of thousands of patients served by DayTwo. The company’s
ability to make precision medicine accessible through their glycemic-control
solution is helping people with diabetes today; I feel fortunate to witness
this as the company expands to the United States.”
DayTwo’s
food-as-medicine approach is based on the original research conducted by
Professors Eran Segal, Ph.D., and Eran Elinav, M.D., Ph.D. at The Weizmann
Institute of Science, published in the journal, Cell, in 2015. The Cell paper
demonstrated how the gut microbiome, in conjunction with other
clinical and personal parameters, can enable personalized dietary interventions
that can successfully balance post-meal glucose response.
Founded in 2015, DayTwo has offices in Tel
Aviv, Israel and San Francisco Bay Area, with 75 employees. The company completed the first quarter of
2019 with tens of thousands of individual customers, and hundreds of providers
in the DayTwo clinician network. DayTwo also launched a strategic partnership
with the world’s second largest HMO, Clalit which now offers the DayTwo
glycemic control solution to its 4.5 million members.
“We partnered with DayTwo to realize the full
potential of personalization in both preventative care and chronic condition
management,” said Irit Poraz, Head Dietitian, at Clalit. “The era of food-as-medicine
is here. DayTwo is a pioneer that has brought the only evidence-based,
actionable microbiome derived solution to the market. We are pleased to be able
to leverage this science and actionability for our plan members.”
DayTwo
continues to conduct ongoing research with clinical institutional partners
including the Weizmann Institute of Science, the Israel Diabetes Association,
Joslin Diabetes Center, Janssen a Pharmaceutical Company of Johnson &
Johnson, and the Mayo Clinic. DayTwo
also depends on the counsel of their elite scientific advisory board composed
of specialists from Tufts School of Nutrition, UCSF, and the Weizmann Institute
of Science. DayTwo has published papers based on their science, results and
work pioneering food-as-medicine offerings in Cell, Cell Metabolism, Nature,
JAMA, and the American Journal of Clinical Nutrition.
_____
About DayTwo
About DayTwo
DayTwo’s
individualized nutrition profile predicts how a person will respond to
different foods and food combinations based on their unique gut microbe
composition and other clinical parameters. DayTwo’s machine-learning-enabled
model is based on technology from a study conducted by Professors Eran Segal,
who holds a Ph.D. in Computer Science and Genetics from Stanford University,
and Immunologist Eran Elinav, M.D., Ph.D. at The Weizmann Institute of Science
in Israel.
Founded in
2015, DayTwo has raised $48 million to date from aMoon, Ofek Ventures, Seventure
Partners, the Mayo Clinic, Johnson & Johnson, and Marius Nacht. DayTwo has
offices in Tel Aviv, Israel and San Francisco Bay Area.
DayTwo is the
only food-as-medicine solution that helps people with diet-related chronic illnesses to balance their blood glucose, including type 2 diabetes and prediabetes. By unlocking the intelligence found in the
microbiome, DayTwo addresses how people process the same food
differently, and can significantly improve predictive and individualized
glycemic response.
